About Scioderm
Scioderm is a company based in Durham (United States) founded in 2012 was acquired by Amicus Therapeutics in August 2015. Scioderm has raised $37 million across 3 funding rounds from investors including Amicus Therapeutics, Redmile Group and Morgenthaler. The company has 6 employees as of December 31, 2015. Scioderm operates in a competitive market with competitors including Alnylam, Ultragenyx, BioMarin Pharmaceutical, Mirum Pharmaceuticals and Homology Medicines, among others.
- Headquarter Durham, United States
- Employees 6 as on 31 Dec, 2015
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Scioderm, Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$37 M (USD)
in 3 rounds
-
Latest Funding Round
$20 M (USD), Series B
Dec 18, 2014
-
Investors
Amicus Therapeutics
& 3 more
-
Employee Count
6
as on Dec 31, 2015
-
Acquired by
Amicus Therapeutics
(Aug 31, 2015)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Scioderm
Scioderm has successfully raised a total of $37M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $20 million completed in December 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Scioderm
Scioderm has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Amicus Therapeutics, Redmile Group and Morgenthaler.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital and private equity investment firm
|
Locked | Locked | Locked | |
|
Investments are made in US life sciences and energy companies.
|
Locked | Locked | Locked | |
|
Operates as an employee-owned hedge fund focused on long/short equity strategies.
|
Locked | Locked | Locked |
Investor details for Scioderm
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Scioderm
Investment portfolio details for Scioderm
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Scioderm
Detailed financials for Scioderm
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Scioderm Comparisons
Peer comparison for Scioderm
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Scioderm
Scioderm operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alnylam, Ultragenyx, BioMarin Pharmaceutical, Mirum Pharmaceuticals and Homology Medicines, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for rare genetic diseases are developed by BioMarin Pharmaceutical.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics are developed for rare diseases treatment.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for rare genetic diseases
|
|
| Locked | Locked | Locked |
Orally deliverable bradykinin B2 antagonists are developed for hereditary angioedema.
|
Detailed competitors of Scioderm
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Scioderm
Complete news archive for Scioderm
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Scioderm
Scioderm was founded in 2012 and raised its 1st funding round 1 year after it was founded.
Scioderm is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
Scioderm is a funded company, having raised a total of $37M across 3 funding rounds to date.
As of Dec 31, 2015, the latest employee count at Scioderm is 6.
Scioderm was founded in 2012 in Durham, United States, within the biotechnology sector. Topical products are developed to meet needs in treating chronic skin diseases. The lead product, SD-101, is advanced for managing skin manifestations of Epidermolysis Bullosa, a rare genetic connective tissue disorder appearing in early life. Operations focus on dermatological innovations for such conditions.
Scioderm's top competitors include Alnylam, UniQure and BioMarin Pharmaceutical.
Scioderm has 4 investors. Key investors include Amicus Therapeutics, Redmile Group, Morgenthaler, and Technology Partners.